ferumoxytol (Rienso®)

Reference No. 145

Publication date:

31/07/2013

Appraisal information

ferumoxytol (Rienso®) 30 mg/ml solution for injection

Company:	Takeda UK Ltd
BNF category:	Nutrition and blood
NMG meeting date:	10/04/2013
AWMSG meeting date:	08/05/2013

Submission Type:	Full Submission
Status:	Marketing authorisation withdrawn
Advice No:	0913
Ratification by Welsh Government:	29/07/2013

Current Progress

Submission
received

NMG
meeting

AWMSG
meeting

Ratification by
Welsh Government

AWMSG advice

LICENCE WITHDRAWN. Please refer to the European Medicines Agency website for further information. Ferumoxytol (Rienso®) is recommended as an option for restricted use within NHS Wales. Ferumoxytol (Rienso®) should only be used for the intravenous treatment of iron deficiency anaemia in non-haemodialysis dependent adult chronic kidney disease patients when oral iron is ineffective or cannot be used. Ferumoxytol (Rienso®) is not recommended for use within NHS Wales outside of this subpopulation of patients. The diagnosis of iron deficiency must be based on appropriate laboratory tests.

Final Appraisal Recommendation (FAR)

Download

ferumoxytol (Rienso) 145 FAR

AWMSG Secretariat Appraisal Report (ASAR)

Download

ferumoxytol (Rienso) 145 ASAR

Clinical Expert (CE) Summary

Download

ferumoxytol (Rienso) 145 CE summary